

Genzyme - Devolved Nations Survey

ONLINE Fieldwork: 28th April - 6th May 2014

Absolutes/col percents

Table 1

Q1. Which one of these regions do you live in?

Base: All respondents

	Gender		Age						Social Grade				Employment Sector		Region		
	Total	Male (a)	Female (b)	18-24 (c)	25-34 (d)	35-44 (e)	45-54 (f)	55-64 (g)	65+ (h)	AB (i)	C1 (j)	C2 (k)	DE (l)	Public (m)	Pri- vate (n)	Wales (o)	Scot- land (p)
Unweighted base	2003	995	1008	208	310	332	354	339	460	714	581	279	429	357	731	1002	1001
Weighted base	2003	1038	965	241	308	322	362	312	457	712	589	277	424	352	740	1002	1001
Wales	1002	516	486	123	149	157	175	157	240	344	310	134	214	184	361	1002	-
	50%	50%	50%	51%	48%	49%	49%	50%	53%	48%	53%	48%	50%	52%	49%	100%p	-
Scotland	1001	522	479	118	159	166	186	155	217	368	279	143	210	168	379	-	1001
	50%	50%	50%	49%	52%	51%	51%	50%	47%	52%	47%	52%	50%	48%	51%	-	100%o

Proportions/Mean: Columns Tested (5% risk level) - a/b - c/d/e/f/g/h - i/j/k/l - m/n - o/p

Genzyme - Devolved Nations Survey

ONLINE Fieldwork: 28th April - 6th May 2014

Absolutes/col percents

Table 2
Q2. Age
Base: All respondents

	Gender			Age						Social Grade				Employment Sector		Region	
	Total	Male (a)	Female (b)	18-24 (c)	25-34 (d)	35-44 (e)	45-54 (f)	55-64 (g)	65+ (h)	AB (i)	C1 (j)	C2 (k)	DE (l)	Public (m)	Private (n)	Wales (o)	Scotland (p)
Unweighted base	2003	995	1008	208	310	332	354	339	460	714	581	279	429	357	731	1002	1001
Weighted base	2003	1038	965	241	308	322	362	312	457	712	589	277	424	352	740	1002	1001
18-24	241 12%	64 6%	177 18%a	241 100%defgh	-	-	-	-	-	53 7%	121 21%ikl	24 9%	42 10%	23 6%	87 12% ^m	123 12%	118 12%
25-34	308 15%	129 12%	180 19%a	-	308 100%ce ^g fh	-	-	-	-	114 16%	86 15%	48 17%	61 14%	72 20%	171 23%	149 15%	159 16%
35-44	322 16%	172 17%	150 16%	-	-	322 100%cd ^g fh	-	-	-	105 15%	96 16%	49 18%	72 17%	101 29% ⁿ	151 20%	157 16%	166 17%
45-54	362 18%	188 18%	174 18%	-	-	-	362 100%cd ^e gh	-	-	103 14%	98 17%	67 24% ^{ij}	94 22% ^{ij}	97 28%	180 24%	175 18%	186 19%
55-64	312 16%	208 20% ^b	105 11%	-	-	-	-	312 100%cd ^e fh	-	114 16%	74 13%	48 17%	77 18% ^j	48 14%	103 14%	157 16%	155 15%
65+	457 23%	278 27% ^b	179 19%	-	-	-	-	-	457 100%cd ^e fg	224 31% ^{ijkl}	113 19%	41 15%	78 18%	11 3%	49 7% ^m	240 24%	217 22%
Mean	47.80	51.38 ^b	43.94	21.24	30.37 ^c	39.83 ^{cd}	49.57 ^{cd}	59.61 ^{cd}	69.72 ^{cd}	51.01 ^{jk}	44.34	47.01 ^j	47.71 ^j	42.85	42.39	48.06	47.53
Standard deviation	16.84	15.73	17.16	1.76	2.78	2.82	3.00	2.79	4.18	17.10	17.45	15.09	15.63	11.62	13.64	17.01	16.68
Standard error	0.38	0.50	0.54	0.12	0.16	0.15	0.16	0.15	0.20	0.64	0.72	0.90	0.75	0.62	0.50	0.54	0.53

Proportions/Means: Columns Tested (5% risk level) - a/b - c/d/e/f/g/h - i/j/k/l - m/n - o/p

Genzyme - Devolved Nations Survey
ONLINE Fieldwork: 28th April - 6th May 2014

Absolutes/col percents

Table 3
Q3. Gender
Base: All respondents

	Gender		Age						Social Grade				Employment Sector		Region		
	Total	Male (a)	Female (b)	18-24 (c)	25-34 (d)	35-44 (e)	45-54 (f)	55-64 (g)	65+ (h)	AB (i)	C1 (j)	C2 (k)	DE (l)	Public (m)	Pri-vate (n)	Wales (o)	Scot-land (p)
Unweighted base	2003	995	1008	208	310	332	354	339	460	714	581	279	429	357	731	1002	1001
Weighted base	2003	1038	965	241	308	322	362	312	457	712	589	277	424	352	740	1002	1001
Male	1038	1038	-	64	129	172	188	208	278	416	292	144	186	164	423	516	522
	52%	100% ^b	-	27%	42% ^c	53% ^{cd}	52% ^{cd}	67% ^{cdef}	61% ^{cdef}	58% ^{jl}	50%	52% ^l	44%	47%	57% ^m	51%	52%
Female	965	-	965	177	180	150	174	105	179	297	297	133	238	188	318	486	479
	48%	-	100% ^a	73% ^{defg}	58% ^{efgh}	47% ^{gh}	48% ^{gh}	33%	39%	42%	50% ⁱ	48%	56% ^{ik}	53% ⁿ	43%	49%	48%

Proportions/Mean: Columns Tested (5% risk level) - a/b - c/d/e/f/g/h - i/j/k/l - m/n - o/p

Genzyme - Devolved Nations Survey

ONLINE Fieldwork: 28th April - 6th May 2014

Absolutes/col percents

Table 4
Q4. Social Grade
Base: All respondents

	Gender		Age						Social Grade				Employment Sector		Region		
	Total	Male (a)	Female (b)	18-24 (c)	25-34 (d)	35-44 (e)	45-54 (f)	55-64 (g)	65+ (h)	AB (i)	C1 (j)	C2 (k)	DE (l)	Public (m)	Pri-vate (n)	Wales (o)	Scotland (p)
Unweighted base	2003	995	1008	208	310	332	354	339	460	714	581	279	429	357	731	1002	1001
Weighted base	2003	1038	965	241	308	322	362	312	457	712	589	277	424	352	740	1002	1001
A	209 10%	127 12% ^b	82 8%	20 8%	16 5%	30 9% ^d	24 7%	39 12% ^{df}	81 18% ^{cdef}	209 29% ^{ijkl}	-	-	-	31 9%	65 9%	94 9%	114 11%
B	504 25%	289 28% ^b	215 22%	33 14%	98 32% ^{cefg}	75 23% ^c	79 22% ^c	75 24% ^c	144 31% ^{cefg}	504 71% ^{ijkl}	-	-	-	120 34% ⁿ	181 24%	250 25%	254 25%
C1	589 29%	292 28%	297 31%	121 50% ^{defgh}	86 28%	96 30%	98 27%	74 24%	113 25%	-	589 100% ^{ikl}	-	-	117 33%	238 32%	310 31%	279 28%
C2	277 14%	144 14%	133 14%	24 10%	48 15% ^h	49 15% ^h	67 19% ^{ch}	48 15% ^h	41 9%	-	-	277 100% ^{ijl}	-	45 13%	146 20% ^m	134 13%	143 14%
D	197 10%	84 8%	113 12% ^a	25 11% ^h	40 13% ^h	32 10% ^h	44 12% ^h	30 10% ^h	26 6%	-	-	-	197 46% ^{ijk}	37 11%	108 15%	107 11%	90 9%
E	228 11%	103 10%	125 13% ^a	17 7%	21 7%	40 12% ^{cd}	50 14% ^{cd}	47 15% ^{cd}	52 11% ^d	-	-	-	228 54% ^{ijk}	2 1%	3 *	107 11%	120 12%
NET: AB	712 36%	416 40% ^b	297 31%	53 22%	114 37% ^{cf}	105 32% ^c	103 28%	114 36% ^{cf}	224 49% ^{cde}	712 100% ^{ijkl}	-	-	-	151 43% ⁿ	246 33%	344 34%	368 37%
NET: DE	424 21%	186 18%	238 25% ^a	42 18%	61 20%	72 22%	94 26% ^{ch}	77 25% ^h	78 17%	-	-	-	424 100% ^{ijk}	39 11%	111 15%	214 21%	210 21%

Proportions/Mean: Columns Tested (5% risk level) - a/b - c/d/e/f/g/h - i/j/k/l - m/n - o/p

Genzyme - Devolved Nations Survey

ONLINE Fieldwork: 28th April - 6th May 2014

Absolutes/col percents

Table 5
Q5a. Which of the following best describes your current working status?
Base: All respondents

	Total	Gender		Age						Social Grade				Employment Sector		Region	
		Male (a)	Female (b)	18-24 (c)	25-34 (d)	35-44 (e)	45-54 (f)	55-64 (g)	65+ (h)	AB (i)	C1 (j)	C2 (k)	DE (l)	Public (m)	Pri-vate (n)	Wales (o)	Scotland (p)
Unweighted base	2003	995	1008	208	310	332	354	339	460	714	581	279	429	357	731	1002	1001
Weighted base	2003	1038	965	241	308	322	362	312	457	712	589	277	424	352	740	1002	1001
NET: Working	1092	587	505	110	243	253	277	151	59	397	355	190	150	352	740	545	547
	55%	57%	52%	45%h	79%cgh	78%cgh	77%cgh	48%h	13%	56%l	60%l	69%ijl	35%	100%	100%	54%	55%
Working full time - working 30 hours per week or more	785	483	302	62	199	194	209	105	15	311	261	128	85	270	514	389	395
	39%	47%b	31%	26%h	65%cgh	60%cgh	58%cgh	34%h	3%	44%l	44%l	46%l	20%	77%n	69%	39%	39%
Working part time - working between 8 and 29 hours per week	308	104	204	48	44	59	68	46	44	86	95	62	65	82	226	156	152
	15%	10%	21%a	20%h	14%h	18%h	19%h	15%h	10%	12%	16%i	22%ijl	15%	23%	31%m	16%	15%
NET: Not working	266	120	146	120	34	41	36	35	1	42	93	13	118	-	-	123	143
	13%	12%	15%a	50%defgh	11%h	13%h	10%h	11%h	*	6%	16%ik	5%	28%ijk	-	-	12%	14%
Not working but seeking work or temporarily unemployed or sick	106	53	54	20	23	27	23	13	-	14	19	4	70	-	-	43	63
	5%	5%	6%	8%gh	8%h	8%gh	6%h	4%h	-	2%	3%	1%	17%ijk	-	-	4%	6%o
Not working and not seeking work / Student	160	67	93	100	11	14	13	22	1	29	75	9	47	-	-	80	80
	8%	6%	10%a	41%defgh	4%h	4%h	4%h	7%dfh	*	4%	13%ik	3%	11%ik	-	-	8%	8%
Retired on a state pension only	88	30	58	-	-	-	-	9	79	11	9	8	59	-	-	48	39
	4%	3%	6%a	-	-	-	-	3%cdef	17%cdefg	2%	1%	3%	14%ijk	-	-	5%	4%
Retired with a private pension	417	280	137	-	-	1	4	98	314	236	115	40	25	-	-	212	205
	21%	27%b	14%	-	-	*	1%	31%cdef	69%cdefg	33%ijkl	19%l	14%l	6%	-	-	21%	20%
House person, housewife, househusband, etc.	140	21	119	12	32	28	45	20	4	25	17	25	72	-	-	74	66
	7%	2%	12%a	5%h	10%ch	9%h	13%cgh	6%h	1%	4%	3%	9%ij	17%ijk	-	-	7%	7%

Proportions/Mean: Columns Tested (5% risk level) - a/b - c/d/e/f/g/h - i/j/k/l - m/n - o/p

Prepared by Populus
 Commissioned and funded by Genzyme Therapeutics Limited

Genzyme - Devolved Nations Survey

ONLINE Fieldwork: 28th April - 6th May 2014

Absolutes/col percents

Table 6
Q5b. Do you work in any of the following occupations?
Base: All respondents

	Gender			Age						Social Grade				Employment Sector		Region	
	Total	Male (a)	Female (b)	18-24 (c)	25-34 (d)	35-44 (e)	45-54 (f)	55-64 (g)	65+ (h)	AB (i)	C1 (j)	C2 (k)	DE (l)	Public (m)	Pri-vate (n)	Wales (o)	Scotland (p)
Unweighted base	1088	562	526	95	243	259	270	162	59	396	352	190	150	357	731	550	538
Weighted base	1092	587	505	110*	243	253	277	151	59*	397	355	190	150	352	740	545	547
NET: Public Sector	352	164	188	23	72	101	97	48	11	151	117	45	39	352	-	184	168
	32%	28%	37%a	21%	29%	40%cdh	35%ch	32%h	18%	38%kl	33%k	23%	26%	100%n	-	34%	31%
Other public sector occupation (please specify as much detail as possible)	80	36	44	6	10	21	29	12	2	24	22	18	16	80	-	33	47
	7%	6%	9%	6%	4%	9%d	10%d	8%	3%	6%	6%	9%	11%	23%n	-	6%	9%
National Health Service	70	22	48	9	21	18	16	6	1	26	24	10	10	70	-	34	36
	6%	4%	10%a	8%	9%	7%	6%	4%	2%	7%	7%	5%	7%	20%n	-	6%	7%
Teaching employed by local education authority including voluntary aided schools and foundation schools	50	15	35	5	10	13	10	8	5	36	10	3	1	50	-	29	21
	5%	3%	7%a	4%	4%	5%	3%	5%	8%	9%jkl	3%	2%	1%	14%n	-	5%	4%
Local government administration	47	25	23	-	4	17	15	9	2	13	26	4	4	47	-	28	20
	4%	4%	5%	-	2%	7%cd	6%cd	6%cd	3%	3%	7%ikl	2%	2%	13%n	-	5%	4%
Universities and Academies funded by government	35	18	17	1	11	7	10	5	-	18	15	1	1	35	-	21	13
	3%	3%	3%	1%	5%	3%	4%	4%	-	5%kl	4%kl	*	1%	10%n	-	4%	2%
Central government including all administrative departments and central government agencies such as the Bank of England	29	19	11	-	5	11	11	2	-	19	6	3	1	29	-	17	12
	3%	3%	2%	-	2%	4%c	4%c	1%	-	5%jl	2%	2%	1%	8%n	-	3%	2%

Proportions/Means: Columns Tested (5% risk level) - a/b - c/d/e/f/g/h - i/j/k/l - m/n - o/p
 * small base

Prepared by Populus
 Commissioned and funded by Genzyme Therapeutics Limited

Genzyme - Devolved Nations Survey

ONLINE Fieldwork: 28th April - 6th May 2014

Absolutes/col percents

Table 6
Q5b. Do you work in any of the following occupations?
Base: All respondents

	Gender			Age						Social Grade				Employment Sector		Region	
	Total	Male (a)	Female (b)	18-24 (c)	25-34 (d)	35-44 (e)	45-54 (f)	55-64 (g)	65+ (h)	AB (i)	C1 (j)	C2 (k)	DE (l)	Public (m)	Private (n)	Wales (o)	Scotland (p)
Weighted base	1092	587	505	110*	243	253	277	151	59*	397	355	190	150	352	740	545	547
Public corporations such as the Royal Mail or British Nuclear fuels or Driving Standards agency	12 1%	10 2% ^b	2 *	- -	2 1%	4 2%	3 1%	3 2%	- -	1 *	2 1%	5 3% ^{ij}	4 3% ^{ij}	12 3% ⁿ	-	7 1%	5 1%
Police service	12 1%	8 1%	4 1%	- -	6 2% ^f	6 2% ^{fg}	-	-	-	4 1%	8 2% ^k	-	-	12 3% ⁿ	-	6 1%	6 1%
Public sector housing	8 1%	3 1%	5 1%	1 1%	-	3 1%	3 1%	1 1%	-	4 1%	3 1%	-	1 1%	8 2% ⁿ	-	5 1%	3 1%
HM Forces	4 *	4 1%	-	-	2 1%	2 1%	-	-	-	1 *	1 *	1 1%	1 1%	4 1% ⁿ	-	1 *	3 1%
Courts service	3 *	3 1%	-	-	-	-	-	2 1%	1 2% ^{def}	3 1%	-	-	-	3 1% ⁿ	-	2 *	1 *
Bradford and Bingley or Northern Rock Building societies	1 *	1 *	-	-	1 *	-	-	-	-	1 *	-	-	-	1 *	-	1 *	-
None of the above - Private Sector	740 68%	423 72% ^b	318 63%	87 79% ^{ef}	171 71% ^e	151 60%	180 65%	103 68%	49 82% ^{efg}	246 62%	238 67%	146 77% ^{ij}	111 74% ⁱ	-	740 100% ^m	361 66%	379 69%

Proportions/Mean: Columns Tested (5% risk level) - a/b - c/d/e/f/g/h - i/j/k/l - m/n - o/p
 * small base

Genzyme - Devolved Nations Survey

ONLINE Fieldwork: 28th April - 6th May 2014

Absolutes/col percents

Table 7

Q6. To what extent do you agree with the following statements on a scale of 0 to 10 where 0 means you do not agree at all and 10 means you agree entirely?

Base: All respondents

Summary table

		Patients should have access to a treatment based on clinical need, even if this would be individually costly to the NHS because of the rarity of a disease	The NHS should ensure that patients with very rare diseases have the same access to treatment as patients with common diseases, even if it means savings ...
Unweighted base		2003	2003
Weighted base		2003	2003
Agree entirely	(10)	700 35%	680 34%
9	(9)	288 14%	253 13%
8	(8)	426 21%	384 19%
7	(7)	245 12%	257 13%
6	(6)	123 6%	159 8%
5	(5)	132 7%	154 8%
4	(4)	24 1%	47 2%
3	(3)	33 2%	30 1%
2	(2)	16 1%	19 1%
1	(1)	3 *	6 *
Do not agree at all	(0)	14 1%	13 1%

Genzyme - Devolved Nations Survey

ONLINE Fieldwork: 28th April - 6th May 2014

Absolutes/col percents

Table 7

Q6. To what extent do you agree with the following statements on a scale of 0 to 10 where 0 means you do not agree at all and 10 means you agree entirely?

Base: All respondents

Summary table

	Patients should have access to a treatment based on clinical need, even if this would be individually costly to the NHS because of the rarity of a disease	The NHS should ensure that patients with very rare diseases have the same access to treatment as patients with common diseases, even if it means savings ...
Weighted base	2003	2003
NET: 8-10	1414 71%	1317 66%
NET: 4-7	523 26%	618 31%
NET: 0-3	66 3%	68 3%
Mean	8.16	7.99
Standard deviation	1.97	2.07
Standard error	0.04	0.05

Genzyme - Devolved Nations Survey

ONLINE Fieldwork: 28th April - 6th May 2014

Absolutes/col percents

Table 8

Q6. To what extent do you agree with the following statements on a scale of 0 to 10 where 0 means you do not agree at all and 10 means you agree entirely?

Base: All respondents

Patients should have access to a treatment based on clinical need, even if this would be individually costly to the NHS because of the rarity of a disease

		Gender		Age						Social Grade				Employment Sector		Region		
		Total	Male (a)	Female (b)	18-24 (c)	25-34 (d)	35-44 (e)	45-54 (f)	55-64 (g)	65+ (h)	AB (i)	C1 (j)	C2 (k)	DE (l)	Public (m)	Private (n)	Wales (o)	Scotland (p)
Unweighted base		2003	995	1008	208	310	332	354	339	460	714	581	279	429	357	731	1002	1001
Weighted base		2003	1038	965	241	308	322	362	312	457	712	589	277	424	352	740	1002	1001
Agree entirely	(10)	700 35%	356 34%	344 36%	66 27%	101 33%	106 33%	136 38% ^c	119 38% ^c	171 37% ^c	220 31%	186 32%	121 43% ^{ij}	173 41% ^{ij}	113 32%	250 34%	360 36%	340 34%
9	(9)	288 14%	155 15%	133 14%	28 12%	41 13%	52 16%	53 15%	43 14%	70 15%	124 17% ^{ijl}	78 13%	35 12%	52 12%	60 17%	99 13%	145 14%	143 14%
8	(8)	426 21%	216 21%	210 22%	56 23%	59 19%	67 21%	85 23%	64 20%	96 21%	146 20%	144 24% ^k	45 16%	91 22%	74 21%	161 22%	217 22%	209 21%
7	(7)	245 12%	124 12%	121 12%	41 17% ^{fg}	39 13%	45 14%	34 10%	31 10%	55 12%	97 14%	75 13%	31 11%	42 10%	37 11%	94 13%	115 11%	130 13%
6	(6)	123 6%	69 7%	54 6%	11 4%	24 8%	18 6%	22 6%	23 7%	26 6%	49 7%	36 6%	14 5%	24 6%	25 7%	51 7%	51 5%	71 7%
5	(5)	132 7%	63 6%	69 7%	26 11% ^{fgh}	30 10% ^{fgh}	24 7%	17 5%	14 4%	21 5%	45 6%	40 7%	17 6%	30 7%	23 7%	54 7%	70 7%	62 6%
4	(4)	24 1%	13 1%	10 1%	2 1%	4 1%	3 1%	3 1%	6 2%	6 1%	11 2% ^l	10 2% ^l	2 1%	1 *	7 2% ⁿ	4 1%	10 1%	14 1%
3	(3)	33 2%	19 2%	14 1%	10 4% ^{fg}	5 2%	5 2%	3 1%	3 1%	8 2%	11 1%	11 2%	6 2%	6 1%	6 2%	9 1%	14 1%	19 2%
2	(2)	16 1%	10 1%	6 1%	1 1%	4 1%	1 *	3 1%	5 2%	2 *	4 1%	6 1%	3 1%	3 1%	3 1%	9 1%	8 1%	8 1%
1	(1)	3 *	3 *	- -	- -	- -	- -	1 *	2 1%	- -	2 *	1 *	- -	- -	1 *	1 *	3 *	- -
Do not agree at all	(0)	14 1%	9 1%	4 *	- -	2 1%	3 1%	3 1%	4 1%	2 *	6 1%	3 1%	3 1%	2 *	2 *	8 1%	9 1%	5 *

Proportions/Mean: Columns Tested (5% risk level) - a/b - c/d/e/f/g/h - i/j/k/l - m/n - o/p

Prepared by Populus
Commissioned and funded by Genzyme Therapeutics Limited

Genzyme - Devolved Nations Survey

ONLINE Fieldwork: 28th April - 6th May 2014

Absolutes/col percents

Table 8

Q6. To what extent do you agree with the following statements on a scale of 0 to 10 where 0 means you do not agree at all and 10 means you agree entirely?

Base: All respondents

Patients should have access to a treatment based on clinical need, even if this would be individually costly to the NHS because of the rarity of a disease

	Gender			Age						Social Grade				Employment Sector		Region	
	Total	Male (a)	Female (b)	18-24 (c)	25-34 (d)	35-44 (e)	45-54 (f)	55-64 (g)	65+ (h)	AB (i)	C1 (j)	C2 (k)	DE (l)	Public (m)	Pri- vate (n)	Wales (o)	Scot- land (p)
Weighted base	2003	1038	965	241	308	322	362	312	457	712	589	277	424	352	740	1002	1001
NET: 8-10	1414 71%	727 70%	687 71%	151 63%	201 65%	225 70%	275 76%cd	226 72%cd	337 74%cd	490 69%	407 69%	201 72%	316 75%i	248 70%	511 69%	722 72%	692 69%
NET: 4-7	523 26%	269 26%	254 26%	80 33%fgh	97 31%fgh	89 28%f	76 21%	73 23%	108 24%	201 28%l	161 27%	65 23%	97 23%	92 26%	203 27%	246 25%	277 28%
NET: 0-3	66 3%	41 4%	25 3%	11 4%	11 4%	8 3%	11 3%	13 4%	12 3%	22 3%	21 3%	12 4%	11 3%	12 3%	27 4%	34 3%	32 3%
Mean	8.16	8.11	8.21	7.82	7.95	8.15	8.32cd	8.17	8.33cd	8.08	8.04	8.29	8.36ij	8.10	8.08	8.19	8.13
Standard deviation	1.97	2.04	1.89	1.96	2.06	1.91	1.92	2.14	1.84	1.96	1.97	2.12	1.88	1.99	2.03	2.00	1.94
Standard error	0.04	0.06	0.06	0.14	0.12	0.10	0.10	0.12	0.09	0.07	0.08	0.13	0.09	0.11	0.08	0.06	0.06

Proportions/Mean: Columns Tested (5% risk level) - a/b - c/d/e/f/g/h - i/j/k/l - m/n - o/p

Genzyme - Devolved Nations Survey

ONLINE Fieldwork: 28th April - 6th May 2014

Absolutes/col percents

Table 9

Q6. To what extent do you agree with the following statements on a scale of 0 to 10 where 0 means you do not agree at all and 10 means you agree entirely?

Base: All respondents

The NHS should ensure that patients with very rare diseases have the same access to treatment as patients with common diseases, even if it means savings have to be made elsewhere in the NHS

		Gender		Age						Social Grade				Employment Sector		Region		
		Total	Male (a)	Female (b)	18-24 (c)	25-34 (d)	35-44 (e)	45-54 (f)	55-64 (g)	65+ (h)	AB (i)	C1 (j)	C2 (k)	DE (l)	Public (m)	Private (n)	Wales (o)	Scotland (p)
Unweighted base		2003	995	1008	208	310	332	354	339	460	714	581	279	429	357	731	1002	1001
Weighted base		2003	1038	965	241	308	322	362	312	457	712	589	277	424	352	740	1002	1001
Agree entirely	(10)	680 34%	343 33%	336 35%	66 28%	100 32%	101 31%	134 37% ^c	111 36%	167 37% ^c	221 31%	177 30%	116 42% ^{ij}	165 39% ^{ij}	117 33%	248 33%	359 36%	320 32%
9	(9)	253 13%	123 12%	130 13%	28 12%	26 8%	38 12%	55 15% ^d	43 14% ^d	64 14% ^d	94 13%	70 12%	34 12%	55 13%	46 13%	85 12%	130 13%	124 12%
8	(8)	384 19%	201 19%	183 19%	42 18%	61 20%	64 20%	64 18%	89 21%	141 20% ^k	125 21% ^k	38 14%	81 19%	62 18%	150 20%	178 18%	206 21%	
7	(7)	257 13%	120 12%	138 14%	42 17% ^{gh}	46 15% ^g	44 14%	45 13%	28 9%	52 11%	92 13%	87 15% ^l	34 12%	45 11%	47 13%	98 13%	135 13%	122 12%
6	(6)	159 8%	94 9%	65 7%	27 11% ^f	29 9% ^f	28 9%	20 5%	22 7%	33 7%	59 8%	53 9% ^k	14 5%	33 8%	30 9%	60 8%	75 7%	84 8%
5	(5)	154 8%	78 7%	76 8%	20 8%	31 10% ^h	32 10% ^h	22 6%	22 7%	26 6%	50 7%	42 7%	30 11%	32 8%	28 8%	60 8%	76 8%	78 8%
4	(4)	47 2%	28 3%	19 2%	8 3%	7 2%	8 2%	5 1%	9 3%	11 2%	25 3% ^k	12 2%	3 1%	7 2%	12 3%	15 2%	12 1%	35 3% ^o
3	(3)	30 1%	20 2%	10 1%	3 1%	4 1%	3 1%	6 2%	6 2%	7 2%	13 2%	9 2%	4 2%	4 1%	8 2% ⁿ	5 1%	11 1%	19 2%
2	(2)	19 1%	16 2% ^b	3 *	3 1%	3 1%	1 *	4 1%	4 1%	4 1%	8 1%	9 1%	1 *	1 *	2 1%	8 1%	14 1% ^p	5 1%
1	(1)	6 *	6 1% ^b	- -	- -	1 *	2 1%	1 *	1 *	1 *	4 1%	2 *	- -	- -	1 *	3 *	4 *	2 *
Do not agree at all	(0)	13 1%	8 1%	4 *	2 1%	1 *	1 *	4 1%	2 1%	2 *	5 1%	3 1%	3 1%	1 *	- -	7 1%	8 1%	5 1%

Proportions/Mean: Columns Tested (5% risk level) - a/b - c/d/e/f/g/h - i/j/k/l - m/n - o/p

Prepared by Populus
Commissioned and funded by Genzyme Therapeutics Limited

Genzyme - Devolved Nations Survey

ONLINE Fieldwork: 28th April - 6th May 2014

Absolutes/col percents

Table 9

Q6. To what extent do you agree with the following statements on a scale of 0 to 10 where 0 means you do not agree at all and 10 means you agree entirely?

Base: All respondents

The NHS should ensure that patients with very rare diseases have the same access to treatment as patients with common diseases, even if it means savings have to be made elsewhere in the NHS

	Gender		Age						Social Grade				Employment Sector		Region		
	Total	Male (a)	Female (b)	18-24 (c)	25-34 (d)	35-44 (e)	45-54 (f)	55-64 (g)	65+ (h)	AB (i)	C1 (j)	C2 (k)	DE (l)	Public (m)	Private (n)	Wales (o)	Scotland (p)
Weighted base	2003	1038	965	241	308	322	362	312	457	712	589	277	424	352	740	1002	1001
NET: 8-10	1317	668	650	137	186	203	253	218	320	456	372	188	301	224	483	667	650
	66%	64%	67%	57%	60%	63%	70% ^{cde}	70% ^{cd}	70% ^{cde}	64%	63%	68%	71% ^{ij}	64%	65%	67%	65%
NET: 4-7	618	320	298	96	113	113	93	81	122	226	195	80	117	117	233	299	319
	31%	31%	31%	40% ^{fgh}	37% ^{fgh}	35% ^{fgh}	26%	26%	27%	32%	33%	29%	28%	33%	32%	30%	32%
NET: 0-3	68	50	18	8	9	7	16	13	15	31	23	9	6	11	24	37	31
	3%	5% ^b	2%	3%	3%	2%	4%	4%	3%	4% ^l	4% ^l	3%	1%	3%	3%	4%	3%
Mean	7.99	7.86	8.13 ^a	7.68	7.83	7.89	8.15 ^c	8.05	8.16 ^{cd}	7.85	7.87	8.18 ^{ij}	8.27 ^{ij}	7.95	7.95	8.06	7.92
Standard deviation	2.07	2.20	1.90	2.09	2.05	2.01	2.12	2.13	2.00	2.16	2.05	2.12	1.86	2.03	2.10	2.08	2.05
Standard error	0.05	0.07	0.06	0.14	0.12	0.11	0.11	0.12	0.09	0.08	0.08	0.13	0.09	0.11	0.08	0.07	0.06

Proportions/Mean: Columns Tested (5% risk level) - a/b - c/d/e/f/g/h - i/j/k/l - m/n - o/p

Genzyme - Devolved Nations Survey

ONLINE Fieldwork: 28th April - 6th May 2014

Absolutes/col percents

Table 10

Q7. Given the state of NHS finances, the NHS might decide that a medicine, which it has been buying for years at the same price, is now “too expensive” to be provided by the NHS. The patients who have been taking the medicine would have no alternative treatment available. Should this be allowed?

Base: All respondents

	Gender		Age						Social Grade				Employment Sector		Region		
	Total	Male (a)	Female (b)	18-24 (c)	25-34 (d)	35-44 (e)	45-54 (f)	55-64 (g)	65+ (h)	AB (i)	C1 (j)	C2 (k)	DE (l)	Public (m)	Private (n)	Wales (o)	Scotland (p)
Unweighted base	2003	995	1008	208	310	332	354	339	460	714	581	279	429	357	731	1002	1001
Weighted base	2003	1038	965	241	308	322	362	312	457	712	589	277	424	352	740	1002	1001
Yes	147 7%	95 9% ^b	52 5%	17 7%	32 10% ^h	21 7%	25 7%	25 8%	27 6%	54 8% ^l	53 9% ^l	23 8% ^l	17 4%	28 8%	64 9%	74 7%	73 7%
No	1699 85%	865 83%	835 86%	199 83%	245 79%	264 82%	319 88% ^{de}	271 87% ^d	401 88% ^{de}	614 86%	487 83%	237 85%	361 85%	294 83%	615 83%	856 85%	843 84%
Don't know	157 8%	78 7%	79 8%	25 10% ^{fg}	32 10% ^{fgh}	37 11% ^{fgh}	18 5%	16 5%	29 6%	44 6%	49 8%	18 7%	46 11% ⁱ	31 9%	61 8%	72 7%	85 8%

Proportions/Means: Columns Tested (5% risk level) - a/b - c/d/e/f/g/h - i/j/k/l - m/n - o/p

Genzyme - Devolved Nations Survey

ONLINE Fieldwork: 28th April - 6th May 2014

Absolutes/col percents

Table 11

Q8. Medicines are approved for use on a European basis by the European Medicines Agency. Should every EU country pay the same price for a particular medicine?

Base: All respondents

	Gender		Age						Social Grade				Employment Sector		Region		
	Total	Male (a)	Female (b)	18-24 (c)	25-34 (d)	35-44 (e)	45-54 (f)	55-64 (g)	65+ (h)	AB (i)	C1 (j)	C2 (k)	DE (l)	Public (m)	Pri-vate (n)	Wales (o)	Scot-land (p)
Unweighted base	2003	995	1008	208	310	332	354	339	460	714	581	279	429	357	731	1002	1001
Weighted base	2003	1038	965	241	308	322	362	312	457	712	589	277	424	352	740	1002	1001
Yes	1543 77%	786 76%	757 78%	186 77%	222 72%	242 75%	291 80% ^d	234 75%	369 81% ^{dg}	543 76%	446 76%	224 81%	329 78%	268 76%	560 76%	783 78%	760 76%
No	179 9%	118 11% ^b	61 6%	23 10%	34 11%	29 9%	26 7%	29 9%	36 8%	71 10% ^l	59 10% ^l	21 8%	27 6%	34 10%	77 10%	92 9%	86 9%
Don't know	281 14%	134 13%	147 15%	32 13%	53 17% ^h	51 16%	45 12%	49 16%	52 11%	98 14%	83 14%	32 12%	68 16%	50 14%	104 14%	127 13%	155 15%

Proportions/Means: Columns Tested (5% risk level) - a/b - c/d/e/f/g/h - i/j/k/l - m/n - o/p

Genzyme - Devolved Nations Survey
ONLINE Fieldwork: 28th April - 6th May 2014

Absolutes/col percents

Table 12

Q9. Do you think it is justified that a pharmaceutical company makes a profit on the drugs it has developed so that it can invest in the development of new medicines for the future?

Base: All respondents

	Gender		Age						Social Grade				Employment Sector		Region		
	Total	Male (a)	Female (b)	18-24 (c)	25-34 (d)	35-44 (e)	45-54 (f)	55-64 (g)	65+ (h)	AB (i)	C1 (j)	C2 (k)	DE (l)	Public (m)	Private (n)	Wales (o)	Scotland (p)
Unweighted base	2003	995	1008	208	310	332	354	339	460	714	581	279	429	357	731	1002	1001
Weighted base	2003	1038	965	241	308	322	362	312	457	712	589	277	424	352	740	1002	1001
Yes	1595 80%	867 84% ^b	728 75%	172 71%	226 73%	241 75%	296 82% ^{cde}	259 83% ^{cde}	401 88% ^{cdef}	603 85% ^{kl}	477 81% ^{kl}	207 75%	307 72%	291 83% ⁿ	569 77%	805 80%	790 79%
No	236 12%	102 10%	134 14% ^a	44 18% ^{fgh}	43 14% ^{gh}	46 14% ^{gh}	43 12%	24 8%	36 8%	68 10%	62 10%	44 16% ^{ij}	62 15% ^{ij}	36 10%	105 14%	105 10%	131 13%
Don't know	173 9%	69 7%	103 11% ^a	26 11% ^h	39 13% ^{fh}	36 11% ^{fh}	23 6%	30 9% ^h	20 4%	41 6%	50 9%	26 9% ⁱ	55 13% ^{ij}	26 7%	66 9%	93 9%	80 8%

Proportions/Means: Columns Tested (5% risk level) - a/b - c/d/e/f/g/h - i/j/k/l - m/n - o/p

Genzyme - Devolved Nations Survey

ONLINE Fieldwork: 28th April - 6th May 2014

Absolutes/col percents

Table 13

Q10. What would you consider a “reasonable profit” for a company that researches, develops and manufactures medicines?

Base: All respondents

	Gender			Age						Social Grade				Employment Sector		Region	
	Total	Male (a)	Female (b)	18-24 (c)	25-34 (d)	35-44 (e)	45-54 (f)	55-64 (g)	65+ (h)	AB (i)	C1 (j)	C2 (k)	DE (l)	Public (m)	Private (n)	Wales (o)	Scotland (p)
Unweighted base	2003	995	1008	208	310	332	354	339	460	714	581	279	429	357	731	1002	1001
Weighted base	2003	1038	965	241	308	322	362	312	457	712	589	277	424	352	740	1002	1001
0%	17 1%	5 1%	12 1%	1 *	8 3%gh	2 1%	5 1%	1 *	1 *	5 1%	4 1%	4 1%	5 1%	2 1%	11 2%	7 1%	10 1%
5%	307 15%	168 16%	140 14%	43 18%g	55 18%g	63 20%fgh	50 14%	37 12%	59 13%	97 14%	95 16%	47 17%	68 16%	62 18%	109 15%	165 16%	142 14%
10%	730 36%	360 35%	369 38%	104 43%gh	133 43%gh	121 38%h	129 36%	107 34%	135 30%	256 36%	216 37%	102 37%	155 37%	133 38%	286 39%	371 37%	359 36%
15%	349 17%	183 18%	166 17%	40 17%	40 13%	45 14%	69 19%d	60 19%d	94 21%de	124 17%	99 17%	47 17%	78 18%	60 17%	126 17%	170 17%	179 18%
20%	465 23%	247 24%	218 23%	37 15%	55 18%	75 23%c	89 25%cd	81 26%cd	127 28%cd	177 25%	135 23%	62 22%	92 22%	85 24%	156 21%	225 22%	240 24%
More than 20%	(25) 7%	74 7%	60 6%	15 6%	17 6%	17 5%	19 5%	26 8%	40 9%	54 8%	39 7%	16 6%	26 6%	11 3%	52 7% ^m	64 6%	71 7%
Mean	13.35	13.48	13.21	12.37	12.13	12.76	13.40 ^{cd}	14.21 ^{cd}	14.47 ^{cd}	13.73	13.25	12.97	13.09	12.77	13.13	13.16	13.54
Standard deviation	6.02	6.07	5.97	5.76	6.03	6.03	5.90	5.93	6.03	6.03	6.02	6.04	5.98	5.69	6.06	6.00	6.04
Standard error	0.13	0.19	0.19	0.40	0.34	0.33	0.31	0.32	0.28	0.23	0.25	0.36	0.29	0.30	0.22	0.19	0.19

Proportions/Means: Columns Tested (5% risk level) - a/b - c/d/e/f/g/h - i/j/k/l - m/n - o/p

Genzyme - Devolved Nations Survey

ONLINE Fieldwork: 28th April - 6th May 2014

Absolutes/col percents

Table 14

Q11. In general, because of the large costs of development, the rarer the disease the higher the price for new treatments which aim to improve both life expectancy and clinical outcomes for patients with that disease. Very rare diseases tend to affect about one in 50,000 individuals (about 60 people in Wales/ about 100 people in Scotland). To what extent do you agree with the following statements on a scale of 0 to 10 where 0 means you do not agree at all and 10 means you agree entirely?

Base: All respondents

Summary table

		People with very rare diseases in Wales/ Scotland should have access to the same treatments and services as people in England	There should be a maximum price that the NHS will pay for treating people with very rare diseases	Funding for treatments for very rare diseases should be "ring-fenced" within the NHS budget	If the NHS has to cut costs in the future, it should start by no longer providing treatments for very rare diseases
Unweighted base		2003	2003	2003	2003
Weighted base		2003	2003	2003	2003
Agree entirely	(10)	1250 62%	105 5%	267 13%	28 1%
9	(9)	242 12%	60 3%	135 7%	15 1%
8	(8)	196 10%	166 8%	236 12%	54 3%
7	(7)	92 5%	188 9%	225 11%	72 4%
6	(6)	67 3%	150 8%	194 10%	79 4%
5	(5)	104 5%	348 17%	487 24%	235 12%
4	(4)	14 1%	109 5%	85 4%	114 6%
3	(3)	14 1%	155 8%	95 5%	191 10%
2	(2)	8 *	171 9%	90 4%	266 13%
1	(1)	5 *	153 8%	59 3%	238 12%
Do not agree at all	(0)	12 1%	397 20%	131 7%	712 36%

Genzyme - Devolved Nations Survey

ONLINE Fieldwork: 28th April - 6th May 2014

Absolutes/col percents

Table 14

Q11. In general, because of the large costs of development, the rarer the disease the higher the price for new treatments which aim to improve both life expectancy and clinical outcomes for patients with that disease. Very rare diseases tend to affect about one in 50,000 individuals (about 60 people in Wales/ about 100 people in Scotland). To what extent do you agree with the following statements on a scale of 0 to 10 where 0 means you do not agree at all and 10 means you agree entirely?

Base: All respondents

Summary table

	People with very rare diseases in Wales/ Scotland should have access to the same treatments and services as people in England	There should be a maximum price that the NHS will pay for treating people with very rare diseases	Funding for treatments for very rare diseases should be "ring-fenced" within the NHS budget	If the NHS has to cut costs in the future, it should start by no longer providing treatments for very rare diseases
Weighted base	2003	2003	2003	2003
NET: 8-10	1687 84%	330 16%	638 32%	97 5%
NET: 4-7	276 14%	796 40%	991 49%	500 25%
NET: 0-3	39 2%	877 44%	374 19%	1407 70%
Mean	8.95	4.13	5.89	2.39
Standard deviation	1.82	3.09	2.82	2.55
Standard error	0.04	0.07	0.06	0.06

Genzyme - Devolved Nations Survey

ONLINE Fieldwork: 28th April - 6th May 2014

Absolutes/col percents

Table 15

Q11. In general, because of the large costs of development, the rarer the disease the higher the price for new treatments which aim to improve both life expectancy and clinical outcomes for patients with that disease. Very rare diseases tend to affect about one in 50,000 individuals (about 60 people in Wales/ about 100 people in Scotland). To what extent do you agree with the following statements on a scale of 0 to 10 where 0 means you do not agree at all and 10 means you agree entirely?

Base: All respondents

People with very rare diseases in Wales/ Scotland should have access to the same treatments and services as people in England

		Gender		Age						Social Grade				Employment Sector		Region		
		Total	Male (a)	Female (b)	18-24 (c)	25-34 (d)	35-44 (e)	45-54 (f)	55-64 (g)	65+ (h)	AB (i)	C1 (j)	C2 (k)	DE (l)	Public (m)	Pri-vate (n)	Wales (o)	Scotland (p)
Unweighted base		2003	995	1008	208	310	332	354	339	460	714	581	279	429	357	731	1002	1001
Weighted base		2003	1038	965	241	308	322	362	312	457	712	589	277	424	352	740	1002	1001
Agree entirely	(10)	1250 62%	617 59%	633 66%a	144 60%	185 60%	186 58%	232 64%	199 64%	304 67%e	422 59%	357 61%	186 67%i	285 67%ij	216 61%	450 61%	657 66%p	593 59%
9	(9)	242 12%	139 13%	103 11%	18 8%	33 11%	48 15%c	51 14%c	37 12%	54 12%	89 13%	78 13%	28 10%	45 11%	53 15%	93 13%	116 12%	126 13%
8	(8)	196 10%	99 10%	97 10%	24 10%	21 7%	40 12%d	32 9%	35 11%d	44 10%	84 12%kl	63 11%l	21 7%	28 7%	28 8%	77 10%	88 9%	108 11%
7	(7)	92 5%	49 5%	43 4%	16 7%	21 7%g	12 4%	16 4%	10 3%	18 4%	30 4%	29 5%	16 6%	17 4%	12 3%	37 5%	52 5%	40 4%
6	(6)	67 3%	44 4%b	23 2%	13 6%f	17 5%fg	10 3%	6 2%	8 2%	13 3%	30 4%	17 3%	7 3%	13 3%	14 4%	25 3%	27 3%	39 4%
5	(5)	104 5%	56 5%	47 5%	20 8%fh	29 9%fgh	18 6%h	12 3%	14 4%	11 2%	32 4%	31 5%	12 4%	29 7%	23 7%	37 5%	44 4%	60 6%
4	(4)	14 1%	7 1%	7 1%	- -	- -	3 1%	4 1%	5 1%d	2 *	4 1%	4 1%	3 1%	3 1%	3 1%	8 1%	4 *	10 1%
3	(3)	14 1%	11 1%b	3 *	5 2%g	1 *	2 1%	2 1%	1 *	3 1%	6 1%l	5 1%	3 1%l	- -	1 *	3 *	3 *	11 1%o
2	(2)	8 *	3 *	5 1%	1 1%	1 *	- -	1 *	- -	5 1%	5 1%	2 *	- -	1 *	- -	1 *	2 *	6 1%
1	(1)	5 *	2 *	3 *	- -	- -	1 *	2 1%	1 *	1 *	2 *	1 *	1 *	1 *	- -	2 *	3 *	2 *
Do not agree at all	(0)	12 1%	10 1%b	2 *	- -	1 *	3 1%	3 1%	3 1%	2 *	8 1%	2 *	- -	2 *	1 *	8 1%	6 1%	6 1%

Proportions/Mean: Columns Tested (5% risk level) - a/b - c/d/e/f/g/h - i/j/k/l - m/n - o/p

Prepared by Populus
Commissioned and funded by Genzyme Therapeutics Limited

Genzyme - Devolved Nations Survey

ONLINE Fieldwork: 28th April - 6th May 2014

Absolutes/col percents

Table 15

Q11. In general, because of the large costs of development, the rarer the disease the higher the price for new treatments which aim to improve both life expectancy and clinical outcomes for patients with that disease. Very rare diseases tend to affect about one in 50,000 individuals (about 60 people in Wales/ about 100 people in Scotland). To what extent do you agree with the following statements on a scale of 0 to 10 where 0 means you do not agree at all and 10 means you agree entirely?

Base: All respondents

People with very rare diseases in Wales/ Scotland should have access to the same treatments and services as people in England

	Gender		Age						Social Grade				Employment Sector		Region		
	Total	Male (a)	Female (b)	18-24 (c)	25-34 (d)	35-44 (e)	45-54 (f)	55-64 (g)	65+ (h)	AB (i)	C1 (j)	C2 (k)	DE (l)	Public (m)	Pri-vate (n)	Wales (o)	Scotland (p)
Weighted base	2003	1038	965	241	308	322	362	312	457	712	589	277	424	352	740	1002	1001
NET: 8-10	1687	855	833	186	239	274	315	271	403	595	498	235	359	298	619	861	827
	84%	82%	86% ^a	77%	78%	85% ^{cd}	87% ^{cd}	87% ^{cd}	88% ^{cd}	84%	85%	85%	85%	85%	84%	86% ^p	83%
NET: 4-7	276	157	120	49	66	43	38	36	44	95	81	38	62	52	107	127	149
	14%	15%	12%	20% ^{efgh}	21% ^{efgh}	13%	11%	12%	10%	13%	14%	14%	15%	15%	14%	13%	15%
NET: 0-3	39	27	13	6	3	6	8	5	11	22	10	4	4	2	14	14	25
	2%	3% ^b	1%	3%	1%	2%	2%	2%	2%	3% ^l	2%	1%	1%	1%	2%	1%	3%
Mean	8.95	8.83	9.07 ^a	8.70	8.79	8.88	9.04 ^c	9.01	9.12 ^{cd}	8.83	8.95	9.08	9.05	9.00	8.89	9.08 ^p	8.82
Standard deviation	1.82	1.93	1.68	1.93	1.85	1.84	1.82	1.81	1.70	1.97	1.74	1.67	1.75	1.67	1.89	1.70	1.92
Standard error	0.04	0.06	0.05	0.13	0.11	0.10	0.10	0.10	0.08	0.07	0.07	0.10	0.08	0.09	0.07	0.05	0.06

Proportions/Mean: Columns Tested (5% risk level) - a/b - c/d/e/f/g/h - i/j/k/l - m/n - o/p

Genzyme - Devolved Nations Survey

ONLINE Fieldwork: 28th April - 6th May 2014

Absolutes/col percents

Table 16

Q11. In general, because of the large costs of development, the rarer the disease the higher the price for new treatments which aim to improve both life expectancy and clinical outcomes for patients with that disease. Very rare diseases tend to affect about one in 50,000 individuals (about 60 people in Wales/about 100 people in Scotland). To what extent do you agree with the following statements on a scale of 0 to 10 where 0 means you do not agree at all and 10 means you agree entirely?

Base: All respondents

There should be a maximum price that the NHS will pay for treating people with very rare diseases

	Total	Gender		Age						Social Grade				Employment Sector		Region		
		Male (a)	Female (b)	18-24 (c)	25-34 (d)	35-44 (e)	45-54 (f)	55-64 (g)	65+ (h)	AB (i)	C1 (j)	C2 (k)	DE (l)	Public (m)	Pri-vate (n)	Wales (o)	Scotland (p)	
Unweighted base	2003	995	1008	208	310	332	354	339	460	714	581	279	429	357	731	1002	1001	
Weighted base	2003	1038	965	241	308	322	362	312	457	712	589	277	424	352	740	1002	1001	
Agree entirely	(10)	105 5%	64 6% ^b	41 4%	7 3%	14 5%	11 3%	27 7% ^{ce}	17 5%	29 6%	24 3%	33 6%	15 5%	32 8% ⁱ	14 4%	33 4%	53 5%	52 5%
9	(9)	60 3%	30 3%	30 3%	8 3%	5 2%	9 3%	9 2%	10 3%	19 4%	19 3%	21 4%	9 3%	11 3%	8 2%	20 3%	31 3%	29 3%
8	(8)	166 8%	101 10% ^b	64 7%	21 9%	32 10% ^f	21 7%	21 6%	22 7%	48 11% ^f	74 10% ^{jk}	43 7%	15 5%	33 8%	23 7%	65 9%	83 8%	82 8%
7	(7)	188 9%	115 11% ^b	73 8%	21 9%	24 8%	41 13% ^{cd}	22 6%	29 9%	51 11% ^f	65 9%	59 10%	28 10%	37 9%	31 9%	71 10%	78 8%	109 11% ^o
6	(6)	150 8%	78 8%	72 7%	18 8%	28 9%	24 8%	25 7%	24 8%	30 7%	59 8%	50 9%	17 6%	25 6%	27 8%	63 8%	81 8%	70 7%
5	(5)	348 17%	174 17%	174 18%	50 21% ^h	69 23% ^{fh}	61 19%	52 14%	52 17%	64 14%	117 16%	102 17%	51 18%	79 19%	66 19%	118 16%	166 17%	182 18%
4	(4)	109 5%	46 4%	63 7% ^a	19 8%	19 6%	17 5%	19 5%	15 5%	21 5%	38 5%	37 6%	12 4%	23 5%	22 6%	40 5%	51 5%	59 6%
3	(3)	155 8%	70 7%	86 9%	28 11%	21 7%	23 7%	28 8%	23 7%	32 7%	62 9%	45 8%	14 5%	35 8%	26 7%	55 7%	87 9%	68 7%
2	(2)	171 9%	84 8%	87 9%	26 11%	22 7%	32 10%	31 8%	20 6%	41 9%	60 8%	62 11% ^l	20 7%	29 7%	38 11%	64 9%	85 8%	86 9%
1	(1)	153 8%	75 7%	78 8%	10 4%	21 7%	26 8%	43 12% ^{cdgh}	21 7%	31 7%	67 9%	38 6%	19 7%	29 7%	40 11%	61 8%	78 8%	75 8%
Do not agree at all	(0)	397 20%	200 19%	198 20%	33 14%	51 17%	57 18%	85 24% ^{cd}	79 25% ^{cde}	91 20%	128 18%	99 17%	78 28% ^{ijl}	92 22%	56 16%	153 21%	209 21%	188 19%

Proportions/Mean: Columns Tested (5% risk level) - a/b - c/d/e/f/g/h - i/j/k/l - m/n - o/p

Prepared by Populus
Commissioned and funded by Genzyme Therapeutics Limited

Genzyme - Devolved Nations Survey

ONLINE Fieldwork: 28th April - 6th May 2014

Absolutes/col percents

Table 16

Q11. In general, because of the large costs of development, the rarer the disease the higher the price for new treatments which aim to improve both life expectancy and clinical outcomes for patients with that disease. Very rare diseases tend to affect about one in 50,000 individuals (about 60 people in Wales/ about 100 people in Scotland). To what extent do you agree with the following statements on a scale of 0 to 10 where 0 means you do not agree at all and 10 means you agree entirely?

Base: All respondents

There should be a maximum price that the NHS will pay for treating people with very rare diseases

	Gender		Age						Social Grade				Employment Sector		Region		
	Total	Male (a)	Female (b)	18-24 (c)	25-34 (d)	35-44 (e)	45-54 (f)	55-64 (g)	65+ (h)	AB (i)	C1 (j)	C2 (k)	DE (l)	Public (m)	Pri-vate (n)	Wales (o)	Scotland (p)
Weighted base	2003	1038	965	241	308	322	362	312	457	712	589	277	424	352	740	1002	1001
NET: 8-10	330 16%	196 19% ^b	135 14%	36 15%	52 17%	41 13%	57 16%	49 16%	96 21% ^e	117 16%	97 17%	39 14%	77 18%	45 13%	118 16%	168 17%	163 16%
NET: 4-7	796 40%	413 40%	383 40%	108 45% ^{fh}	141 46% ^{fh}	144 45% ^{fh}	118 33%	120 38%	166 36%	278 39%	247 42%	107 39%	163 38%	146 42%	291 39%	375 37%	420 42% ^o
NET: 0-3	877 44%	429 41%	448 46% ^a	97 40%	116 38%	138 43%	187 52% ^{cdeh}	143 46% ^d	195 43%	317 44%	244 42%	131 47%	184 43%	161 46%	332 45%	459 46%	418 42%
Mean	4.13	4.34 ^b	3.90	4.31 ^f	4.33 ^f	4.10	3.71	3.96	4.36 ^f	4.10	4.30 ^k	3.78	4.18	3.95	4.05	4.04	4.22
Standard deviation	3.09	3.16	2.99	2.77	2.93	2.93	3.22	3.20	3.24	3.00	3.03	3.23	3.21	2.91	3.08	3.11	3.07
Standard error	0.07	0.10	0.09	0.19	0.17	0.16	0.17	0.17	0.15	0.11	0.13	0.19	0.15	0.15	0.11	0.10	0.10

Proportions/Mean: Columns Tested (5% risk level) - a/b - c/d/e/f/g/h - i/j/k/l - m/n - o/p

Genzyme - Devolved Nations Survey

ONLINE Fieldwork: 28th April - 6th May 2014

Absolutes/col percents

Table 17

Q11. In general, because of the large costs of development, the rarer the disease the higher the price for new treatments which aim to improve both life expectancy and clinical outcomes for patients with that disease. Very rare diseases tend to affect about one in 50,000 individuals (about 60 people in Wales/about 100 people in Scotland). To what extent do you agree with the following statements on a scale of 0 to 10 where 0 means you do not agree at all and 10 means you agree entirely?

Base: All respondents

Funding for treatments for very rare diseases should be "ring-fenced" within the NHS budget

	Total	Gender		Age						Social Grade				Employment Sector		Region		
		Male (a)	Female (b)	18-24 (c)	25-34 (d)	35-44 (e)	45-54 (f)	55-64 (g)	65+ (h)	AB (i)	C1 (j)	C2 (k)	DE (l)	Public (m)	Pri-vate (n)	Wales (o)	Scotland (p)	
Unweighted base	2003	995	1008	208	310	332	354	339	460	714	581	279	429	357	731	1002	1001	
Weighted base	2003	1038	965	241	308	322	362	312	457	712	589	277	424	352	740	1002	1001	
Agree entirely	(10)	267 13%	160 15% ^b	107 11%	12 5%	22 7%	31 10%	55 15% ^{cde}	61 19% ^{cde}	87 19% ^{cde}	100 14%	71 12%	40 14%	57 13%	41 12%	76 10%	140 14%	127 13%
9	(9)	135 7%	73 7%	62 6%	6 3%	11 3%	21 6% ^c	25 7% ^c	23 7% ^{cd}	49 11% ^{cde}	52 7%	39 7%	14 5%	29 7%	26 7%	45 6%	63 6%	71 7%
8	(8)	236 12%	124 12%	112 12%	15 6%	37 12% ^c	38 12% ^c	38 10%	49 16% ^{cf}	60 13% ^c	94 13%	65 11%	36 13%	40 9%	42 12%	92 12%	117 12%	119 12%
7	(7)	225 11%	127 12%	98 10%	27 11%	43 14%	33 10%	38 11%	33 11%	50 11%	81 11%	78 13%	27 10%	39 9%	38 11%	88 12%	103 10%	122 12%
6	(6)	194 10%	102 10%	92 10%	29 12%	32 10%	39 12%	30 8%	28 9%	36 8%	66 9%	56 10%	30 11%	41 10%	37 10%	75 10%	109 11%	85 8%
5	(5)	487 24%	214 21%	273 28% ^{aa}	89 37% ^{defg}	85 27% ^{fgh}	88 27% ^{fgh}	74 21%	65 21%	86 19%	151 21%	138 23%	61 22%	137 32% ^{ijkl}	78 22%	180 24%	236 24%	251 25%
4	(4)	85 4%	38 4%	47 5%	14 6%	18 6% ^g	17 5%	15 4%	7 2%	15 3%	30 4%	29 5%	11 4%	16 4%	15 4%	34 5%	42 4%	43 4%
3	(3)	95 5%	51 5%	43 4%	20 8% ^{eg}	16 5%	8 2%	16 4%	11 4%	24 5% ^e	40 6% ^l	31 5%	11 4%	13 3%	24 7% ⁿ	30 4%	53 5%	41 4%
2	(2)	90 4%	45 4%	44 5%	16 7% ^h	15 5%	14 4%	21 6%	10 3%	14 3%	30 4%	32 5%	11 4%	16 4%	20 6%	34 5%	41 4%	49 5%
1	(1)	59 3%	34 3%	25 3%	4 1%	5 2%	13 4%	19 5% ^{cdg}	7 2%	12 3%	29 4% ^l	15 3%	8 3%	8 2%	12 3%	29 4%	30 3%	29 3%

Proportions/Mean: Columns Tested (5% risk level) - a/b - c/d/e/f/g/h - i/j/k/l - m/n - o/p

Prepared by Populus
Commissioned and funded by Genzyme Therapeutics Limited

Genzyme - Devolved Nations Survey

ONLINE Fieldwork: 28th April - 6th May 2014

Absolutes/col percents

Table 17

Q11. In general, because of the large costs of development, the rarer the disease the higher the price for new treatments which aim to improve both life expectancy and clinical outcomes for patients with that disease. Very rare diseases tend to affect about one in 50,000 individuals (about 60 people in Wales/about 100 people in Scotland). To what extent do you agree with the following statements on a scale of 0 to 10 where 0 means you do not agree at all and 10 means you agree entirely?

Base: All respondents

Funding for treatments for very rare diseases should be "ring-fenced" within the NHS budget

	Total	Gender		Age						Social Grade				Employment Sector		Region	
		Male (a)	Female (b)	18-24 (c)	25-34 (d)	35-44 (e)	45-54 (f)	55-64 (g)	65+ (h)	AB (i)	C1 (j)	C2 (k)	DE (l)	Public (m)	Pri-vate (n)	Wales (o)	Scotland (p)
Weighted base	2003	1038	965	241	308	322	362	312	457	712	589	277	424	352	740	1002	1001
Do not agree at all (0)	131	69	62	9	25	22	32	19	25	40	35	29	28	19	58	69	62
	7%	7%	6%	4%	8% ^c	7%	9% ^c	6%	5%	6%	6%	10% ^{ij}	7%	5%	8%	7%	6%

Proportions/Mean: Columns Tested (5% risk level) - a/b - c/d/e/f/g/h - i/j/k/l - m/n - o/p

Genzyme - Devolved Nations Survey

ONLINE Fieldwork: 28th April - 6th May 2014

Absolutes/col percents

Table 17

Q11. In general, because of the large costs of development, the rarer the disease the higher the price for new treatments which aim to improve both life expectancy and clinical outcomes for patients with that disease. Very rare diseases tend to affect about one in 50,000 individuals (about 60 people in Wales/ about 100 people in Scotland). To what extent do you agree with the following statements on a scale of 0 to 10 where 0 means you do not agree at all and 10 means you agree entirely?

Base: All respondents

Funding for treatments for very rare diseases should be "ring-fenced" within the NHS budget

	Gender		Age						Social Grade				Employment Sector		Region		
	Total	Male (a)	Female (b)	18-24 (c)	25-34 (d)	35-44 (e)	45-54 (f)	55-64 (g)	65+ (h)	AB (i)	C1 (j)	C2 (k)	DE (l)	Public (m)	Private (n)	Wales (o)	Scotland (p)
Weighted base	2003	1038	965	241	308	322	362	312	457	712	589	277	424	352	740	1002	1001
NET: 8-10	638 32%	357 34% ^b	281 29%	34 14%	69 23% ^c	90 28% ^c	117 32% ^{cd}	133 43% ^{cdef}	195 43% ^{cdef}	246 34%	175 30%	91 33%	126 30%	109 31%	213 29%	320 32%	318 32%
NET: 4-7	991 49%	481 46%	510 53% ^a	159 66% ^{efgh}	178 58% ^{fgh}	176 55% ^{fgh}	157 44%	133 43%	187 41%	328 46%	300 51%	128 46%	234 55% ^{ik}	169 48%	377 51%	490 49%	501 50%
NET: 0-3	374 19%	200 19%	174 18%	48 20%	61 20%	56 18%	87 24% ^{egh}	47 15%	75 16%	138 19%	113 19%	58 21%	65 15%	75 21%	150 20%	193 19%	182 18%
Mean	5.89	6.02 ^b	5.76	5.23	5.46	5.69 ^c	5.68	6.46 ^{cde}	6.46 ^{cde}	5.99	5.84	5.76	5.90	5.80	5.66	5.88	5.91
Standard deviation	2.82	2.90	2.73	2.22	2.62	2.73	3.11	2.86	2.88	2.85	2.76	3.03	2.72	2.78	2.83	2.85	2.80
Standard error	0.06	0.09	0.09	0.15	0.15	0.15	0.17	0.16	0.13	0.11	0.11	0.18	0.13	0.15	0.10	0.09	0.09

Proportions/Means: Columns Tested (5% risk level) - a/b - c/d/e/f/g/h - i/j/k/l - m/n - o/p

Genzyme - Devolved Nations Survey

ONLINE Fieldwork: 28th April - 6th May 2014

Absolutes/col percents

Table 18

Q11. In general, because of the large costs of development, the rarer the disease the higher the price for new treatments which aim to improve both life expectancy and clinical outcomes for patients with that disease. Very rare diseases tend to affect about one in 50,000 individuals (about 60 people in Wales/about 100 people in Scotland). To what extent do you agree with the following statements on a scale of 0 to 10 where 0 means you do not agree at all and 10 means you agree entirely?

Base: All respondents

If the NHS has to cut costs in the future, it should start by no longer providing treatments for very rare diseases

		Gender		Age						Social Grade				Employment Sector		Region		
		Total	Male (a)	Female (b)	18-24 (c)	25-34 (d)	35-44 (e)	45-54 (f)	55-64 (g)	65+ (h)	AB (i)	C1 (j)	C2 (k)	DE (l)	Public (m)	Pri-vate (n)	Wales (o)	Scotland (p)
Unweighted base		2003	995	1008	208	310	332	354	339	460	714	581	279	429	357	731	1002	1001
Weighted base		2003	1038	965	241	308	322	362	312	457	712	589	277	424	352	740	1002	1001
Agree entirely	(10)	28 1%	20 2% ^b	8 1%	3 1%	2 1%	8 2%	6 2%	4 1%	5 1%	8 1%	11 2%	7 3% ^l	2 *	2 1%	15 2%	21 2% ^p	7 1%
9	(9)	15 1%	12 1% ^b	3 *	3 1%	- -	4 1%	2 1%	3 1%	3 1%	4 1%	6 1%	2 1%	2 *	1 *	3 *	8 1%	7 1%
8	(8)	54 3%	37 4% ^b	17 2%	6 2%	10 3%	6 2%	11 3%	11 4%	10 2%	23 3%	17 3%	5 2%	9 2%	12 3%	20 3%	27 3%	27 3%
7	(7)	72 4%	41 4%	31 3%	8 3%	18 6% ^g	12 4%	12 3%	8 3%	14 3%	28 4%	20 3%	7 3%	17 4%	4 1%	39 5% ^m	39 4%	33 3%
6	(6)	79 4%	44 4%	35 4%	9 4%	18 6%	12 4%	13 4%	11 4%	15 3%	24 3%	25 4%	9 3%	21 5%	16 5%	29 4%	38 4%	41 4%
5	(5)	235 12%	131 13%	104 11%	30 13%	44 14%	41 13%	35 10%	35 11%	49 11%	89 12%	69 12%	26 9%	52 12%	39 11%	79 11%	112 11%	123 12%
4	(4)	114 6%	50 5%	64 7%	15 6%	28 9% ^{efg}	12 4%	16 5%	16 5%	27 6%	45 6%	33 6%	19 7%	17 4%	25 7%	41 6%	53 5%	61 6%
3	(3)	191 10%	93 9%	98 10%	25 10%	23 8%	39 12% ^f	24 7%	29 9%	51 11% ^f	74 10%	59 10%	18 6%	41 10%	31 9%	67 9%	98 10%	93 9%
2	(2)	266 13%	132 13%	134 14%	45 19% ^{fh}	38 12%	46 14%	43 12%	44 14%	50 11%	89 13%	96 16% ^l	32 11%	49 12%	55 16%	100 14%	123 12%	143 14%
1	(1)	238 12%	113 11%	125 13%	21 9%	35 11%	41 13%	56 16% ^{cg}	30 10%	55 12%	101 14%	62 10%	28 10%	47 11%	53 15%	90 12%	123 12%	115 11%
Do not agree at all	(0)	712 36%	365 35%	347 36%	76 32%	91 30%	102 32%	143 40% ^{de}	121 39% ^d	178 39% ^{de}	226 32%	193 33%	125 45% ^{ij}	168 40% ^{ij}	113 32%	257 35%	361 36%	351 35%

Proportions/Mean: Columns Tested (5% risk level) - a/b - c/d/e/f/g/h - i/j/k/l - m/n - o/p

Prepared by Populus
Commissioned and funded by Genzyme Therapeutics Limited

Genzyme - Devolved Nations Survey

ONLINE Fieldwork: 28th April - 6th May 2014

Absolutes/col percents

Table 18

Q11. In general, because of the large costs of development, the rarer the disease the higher the price for new treatments which aim to improve both life expectancy and clinical outcomes for patients with that disease. Very rare diseases tend to affect about one in 50,000 individuals (about 60 people in Wales/ about 100 people in Scotland). To what extent do you agree with the following statements on a scale of 0 to 10 where 0 means you do not agree at all and 10 means you agree entirely?

Base: All respondents

If the NHS has to cut costs in the future, it should start by no longer providing treatments for very rare diseases

	Gender		Age						Social Grade				Employment Sector		Region		
	Total	Male (a)	Female (b)	18-24 (c)	25-34 (d)	35-44 (e)	45-54 (f)	55-64 (g)	65+ (h)	AB (i)	C1 (j)	C2 (k)	DE (l)	Public (m)	Pri-vate (n)	Wales (o)	Scotland (p)
Weighted base	2003	1038	965	241	308	322	362	312	457	712	589	277	424	352	740	1002	1001
NET: 8-10	97 5%	69 7% ^b	28 3%	12 5%	12 4%	18 5%	19 5%	17 6%	18 4%	36 5%	34 6% ^l	14 5%	13 3%	15 4%	38 5%	55 6%	41 4%
NET: 4-7	500 25%	266 26%	234 24%	63 26%	108 35% ^{cefg} h	78 24%	76 21%	70 22%	105 23%	186 26%	146 25%	60 22%	107 25%	85 24%	188 25%	242 24%	258 26%
NET: 0-3	1407 70%	703 68%	704 73% ^a	167 69%	188 61%	227 70% ^d	266 74% ^d	225 72% ^d	334 73% ^d	490 69%	409 69%	203 73%	304 72%	252 72%	514 69%	705 70%	702 70%
Mean	2.39	2.57 ^b	2.21	2.55	2.76 ^{fg}	2.55	2.16	2.30	2.20	2.49 ^k	2.53 ^k	2.10	2.24	2.29	2.48	2.42	2.36
Standard deviation	2.55	2.71	2.36	2.51	2.55	2.62	2.59	2.56	2.47	2.53	2.60	2.63	2.47	2.35	2.64	2.64	2.47
Standard error	0.06	0.09	0.07	0.17	0.14	0.14	0.14	0.14	0.12	0.09	0.11	0.16	0.12	0.12	0.10	0.08	0.08

Proportions/Means: Columns Tested (5% risk level) - a/b - c/d/e/f/g/h - i/j/k/l - m/n - o/p